Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1988 Aug;47(8):620–627. doi: 10.1136/ard.47.8.620

Effects of prostaglandin E2 on disease activity, gastric secretion and intestinal permeability, and morphology in patients with rheumatoid arthritis.

A E Henriksson 1, C Tagesson 1, A Uribe 1, K Uvnäs-Moberg 1, C E Nord 1, R Gullberg 1, C Johansson 1
PMCID: PMC1006711  PMID: 3166369

Abstract

The effects of oral natural prostaglandin E2 (PGE2) on symptoms, disease activity, and gastrointestinal functions in rheumatoid arthritis (RA) were studied in an open pilot trial. Twelve patients, six taking and six not taking non-steroidal anti-inflammatory drugs (NSAIDs), received 1 mg natural PGE2 three times a day for six weeks. The treatment was tolerated well and the only side effect noted was slightly looser stools in three patients. Half of the patients reported subjective improvement and none had aggravation of symptoms. The Ritchie articular index and several biochemical inflammation markers decreased and were significantly reduced at the end of the treatment period. The thickness of the small intestinal mucosa increased during the PGE2 treatment. The intestinal permeability pattern, measured by urinary excretion of polyethylene glycols (PEG 400), differed between the patients taking and not taking NSAIDs. The initially high urinary PEG 400 excretion values in the patients taking NSAIDs decreased and the initially low excretion values in patients not taking NSAIDs increased during the PGE2 treatment. The jejunal contents became sterile in 5/6 patients not taking NSAIDs and remained sterile in 1/6 patients taking NSAIDs at the end of the treatment. The treatment period was associated with a reduction of lactobacilli in patients not treated with NSAIDs. Thus the treatment appeared to decrease disease activity and to improve small intestinal functions in patients with RA, findings that need confirmation in a controlled trial.

Full text

PDF
620

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aspinall R. L., Cammarata P. S. Effect of prostaglandin E2 on adjuvant arthritis. Nature. 1969 Dec 27;224(5226):1320–1321. doi: 10.1038/2241320a0. [DOI] [PubMed] [Google Scholar]
  2. Bennett J. C. The infectious etiology of rheumatoid arthritis. New considerations. Arthritis Rheum. 1978 Jun;21(5):531–538. doi: 10.1002/art.1780210507. [DOI] [PubMed] [Google Scholar]
  3. Bjarnason I., Williams P., Smethurst P., Peters T. J., Levi A. J. Effect of non-steroidal anti-inflammatory drugs and prostaglandins on the permeability of the human small intestine. Gut. 1986 Nov;27(11):1292–1297. doi: 10.1136/gut.27.11.1292. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Cohen M. M., Cheung G., Lyster D. M. Prevention of aspirin-induced faecal blood loss by prostaglandin E2. Gut. 1980 Jul;21(7):602–606. doi: 10.1136/gut.21.7.602. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Drasar B. S., Shiner M., McLeod G. M. Studies on the intestinal flora. I. The bacterial flora of the gastrointestinal tract in healthy and achlorhydric persons. Gastroenterology. 1969 Jan;56(1):71–79. [PubMed] [Google Scholar]
  6. Ericson S. The parotid gland in subjects with and without rheumatoid arthritis. A sialographic and physiologic study. Acta Radiol Diagn (Stockh) 1968;(Suppl):1+–1+. [PubMed] [Google Scholar]
  7. Gendre J. P., Luboinski J., Prier A., Camus J. P., Le Quintrec Y. Anomalies de la muqueuse jéjunale et polyarthrite rhumatoïde: 30 cas. Gastroenterol Clin Biol. 1982 Oct;6(10):772–775. [PubMed] [Google Scholar]
  8. Gray J. D., Shiner M. Influence of gastric pH on gastric and jejunal flora. Gut. 1967 Dec;8(6):574–581. doi: 10.1136/gut.8.6.574. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Gullberg R. Possible role of alterations of the intestinal flora in rheumatoid arthritis. Rheumatol Rehabil. 1978;Suppl:5–10. doi: 10.1093/rheumatology/xvii.suppl.5. [DOI] [PubMed] [Google Scholar]
  10. Heimdahl A., Nord C. E. Effect of phenoxymethylpenicillin and clindamycin on the oral, throat and faecal microflora of man. Scand J Infect Dis. 1979;11(3):233–242. doi: 10.3109/inf.1979.11.issue-3.11. [DOI] [PubMed] [Google Scholar]
  11. Helander H. F., Johansson C., Blom H., Uribe A. Trophic actions of E2 prostaglandins in the rat gastrointestinal mucosa. A quantitative morphologic study. Gastroenterology. 1985 Dec;89(6):1393–1399. doi: 10.1016/0016-5085(85)90660-2. [DOI] [PubMed] [Google Scholar]
  12. Henriksson K., Uvnäs-Moberg K., Nord C. E., Johansson C., Gullberg R. Gastrin, gastric acid secretion, and gastric microflora in patients with rheumatoid arthritis. Ann Rheum Dis. 1986 Jun;45(6):475–483. doi: 10.1136/ard.45.6.475. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Johansson C., Bergström S. Prostaglandin and protection of the gastroduodenal mucosa. Scand J Gastroenterol Suppl. 1982;77:21–46. [PubMed] [Google Scholar]
  14. Johansson C., Kollberg B., Nordemar R., Samuelson K., Bergström S. Protective effect of prostaglandin E2 in the gastrointestinal tract during indomethacin treatment of rheumatic diseases. Gastroenterology. 1980 Mar;78(3):479–483. [PubMed] [Google Scholar]
  15. Kohashi O., Kohashi Y., Takahashi T., Ozawa A., Shigematsu N. Reverse effect of gram-positive bacteria vs. gram-negative bacteria on adjuvant-induced arthritis in germfree rats. Microbiol Immunol. 1985;29(6):487–497. doi: 10.1111/j.1348-0421.1985.tb00851.x. [DOI] [PubMed] [Google Scholar]
  16. Marcolongo R., Bayeli P. F., Montagnani M. Gastrointestinal involvement in rheumatoid arthritis: a biopsy study. J Rheumatol. 1979 Mar-Apr;6(2):163–173. [PubMed] [Google Scholar]
  17. Miller T. A., Jacobson E. D. Gastrointestinal cytoprotection by prostaglandins. Gut. 1979 Jan;20(1):75–87. doi: 10.1136/gut.20.1.75. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Nilsson G. Increased plasma gastrin levels in connection with inhibition of gastric acid responses to sham feeding following bulbar perfusion with acid in dogs. Scand J Gastroenterol. 1975;10(3):273–277. [PubMed] [Google Scholar]
  19. Pettersson T., Wegelius O., Skrifvars B. Gastro-intestinal disturbances in patients with severe rheumatoid arthritis. Acta Med Scand. 1970 Jul-Aug;1-2(1):139–144. [PubMed] [Google Scholar]
  20. ROPES M. W., BENNETT G. A., COBB S., JACOX R., JESSAR R. A. 1958 Revision of diagnostic criteria for rheumatoid arthritis. Bull Rheum Dis. 1958 Dec;9(4):175–176. [PubMed] [Google Scholar]
  21. Ritchie D. M., Boyle J. A., McInnes J. M., Jasani M. K., Dalakos T. G., Grieveson P., Buchanan W. W. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med. 1968 Jul;37(147):393–406. [PubMed] [Google Scholar]
  22. Rooney J. P., Vince J., Kennedy A. C., Webb J., Lee P., Dick W. C., Buchanan K. D., Hayes J. R., Ardill J., O'Connor F. Hypergastrinaemia in rheumatoid arthritis: disease or iatrogenesis. Br Med J. 1973 Jun 30;2(5869):752–753. doi: 10.1136/bmj.2.5869.752. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Silvoso G. R., Ivey K. J., Butt J. H., Lockard O. O., Holt S. D., Sisk C., Baskin W. N., Mackercher P. A., Hewett J. Incidence of gastric lesions in patients with rheumatic disease on chronic aspirin therapy. Ann Intern Med. 1979 Oct;91(4):517–520. doi: 10.7326/0003-4819-91-4-517. [DOI] [PubMed] [Google Scholar]
  24. Smith M. D., Gibson R. A., Brooks P. M. Abnormal bowel permeability in ankylosing spondylitis and rheumatoid arthritis. J Rheumatol. 1985 Apr;12(2):299–305. [PubMed] [Google Scholar]
  25. Sundqvist T., Lindström F., Magnusson K. E., Sköldstam L., Stjernström I., Tagesson C. Influence of fasting on intestinal permeability and disease activity in patients with rheumatoid arthritis. Scand J Rheumatol. 1982;11(1):33–38. doi: 10.3109/03009748209098111. [DOI] [PubMed] [Google Scholar]
  26. Tagesson C., Bengtsson A. Intestinal permeability to different-sized polyethyleneglycols in patients with rheumatoid arthritis. Scand J Rheumatol. 1983;12(2):124–128. doi: 10.3109/03009748309102897. [DOI] [PubMed] [Google Scholar]
  27. Tytgat G. N., Offerhaus G. J., van Minnen A. J., Everts V., Hensen-Logmans S. C., Samson G. Influence of oral 15(R)-15-methyl prostaglandin E2 on human gastric mucosa. A light microscopic, cell kinetic, and ultrastructural study. Gastroenterology. 1986 May;90(5 Pt 1):1111–1120. doi: 10.1016/0016-5085(86)90375-6. [DOI] [PubMed] [Google Scholar]
  28. Uribe A., Johansson C., Rubio C. Cell proliferation of the rat gastrointestinal mucosa after treatment with E2 prostaglandins and indomethacin. Digestion. 1987;36(4):238–245. doi: 10.1159/000199424. [DOI] [PubMed] [Google Scholar]
  29. Zurier R. B., Sayadoff D. M., Torrey A. B., Rothfield N. F. Prostaglandin E treatment of NZB/NZW mice. Arthritis Rheum. 1977 Mar;20(2):723–728. doi: 10.1002/art.1780200213. [DOI] [PubMed] [Google Scholar]
  30. de Witte T. J., Geerdink P. J., Lamers C. B., Boerbooms A. M., van der Korst J. K. Hypochlorhydria and hypergastrinaemia in rheumatoid arthritis. Ann Rheum Dis. 1979 Feb;38(1):14–17. doi: 10.1136/ard.38.1.14. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES